Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board
Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist for Central Disorders of Hypersomnolence
American Uranium Reports Completed Drilling Strengthens Lo Herma Uranium Resource Upgrade for Upcoming Scoping Study
Homerun Resources Inc. Formally Included in "Programa Desenvolve" Tax Incentive Program to Support Industrial Development and Economic Integration in the State of Bahia, Brazil
Corcel Intersects Skarn-Hosted Copper-Gold Mineralization in Step-Out Drilling Expanding Strike Length to 900m at the Yuma King Project, Arizona
Premier American Uranium Successfully Completes Drilling Program at Cebolleta Project, New Mexico and Delivers Samples for Advanced Metallurgical Testing
